Hugh Yarrow, investment director at Evenlode, tells AlphaScene why he remains bullish on recent pharma laggards AstraZeneca and GlaxoSmithKline.
Hugh Yarrow, investment director at Evenlode, tells AlphaScene why he remains bullish on recent pharma laggards AstraZeneca and GlaxoSmithKline.